Covered recipient · General Payments record
SERGE ALEXANIAN
Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology
General Payments · PY2018–2024
$2,383,106.00
- Reported across 340 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $303,121.11 | 41 |
| Travel and Lodging | $672.46 | 4 |
| Food and Beverage | $384.18 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $276,158.61 | 31 |
| Stemline Therapeutics Inc. | $22,943.15 | 10 |
| ABBVIE INC. | $4,979.28 | 8 |
| Blueprint Medicines Corporation | $96.71 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (51)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $376.65 | 09/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104175026 | CMS |
| ABBVIE INC. | $66.25 | 09/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103201531 | CMS |
| ABBVIE INC. | $50.00 | 09/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103201533 | CMS |
| ABBVIE INC. | $65.57 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103201535 | CMS |
| ABBVIE INC. | $213.06 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104175028 | CMS |
| ABBVIE INC. | $22.75 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104175030 | CMS |
| ABBVIE INC. | $60.00 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104175032 | CMS |
| ABBVIE INC. | $4,125.00 | 11/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131317 | CMS |
| Blueprint Medicines Corporation | $44.98 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147450532 | CMS |
| Blueprint Medicines Corporation | $51.73 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147450618 | CMS |
| Incyte Corporation | $550.00 | 02/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169637 | CMS |
| Incyte Corporation | $6,678.90 | 02/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169903 | CMS |
| Incyte Corporation | $9,687.50 | 03/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169833 | CMS |
| Incyte Corporation | $825.00 | 03/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169645 | CMS |
| Incyte Corporation | $1,512.50 | 03/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169647 | CMS |
| Incyte Corporation | $1,787.50 | 04/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169553 | CMS |
| Incyte Corporation | $11,177.23 | 04/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169935 | CMS |
| Incyte Corporation | $11,600.00 | 05/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169649 | CMS |
| Incyte Corporation | $9,793.92 | 05/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169821 | CMS |
| Incyte Corporation | $26,593.75 | 05/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169937 | CMS |
| Incyte Corporation | $23,200.00 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169651 | CMS |
| Incyte Corporation | $575.00 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169655 | CMS |
| Incyte Corporation | $8,725.99 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169657 | CMS |
| Incyte Corporation | $6,110.85 | 07/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169557 | CMS |
| Incyte Corporation | $37,900.00 | 07/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169659 | CMS |
| Incyte Corporation | $2,875.00 | 07/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169661 | CMS |
| Incyte Corporation | $1,300.00 | 08/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169663 | CMS |
| Incyte Corporation | $15,649.08 | 08/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169665 | CMS |
| Incyte Corporation | $1,006.25 | 08/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169667 | CMS |
| Incyte Corporation | $1,006.25 | 09/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169669 | CMS |
| Incyte Corporation | $9,058.32 | 09/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169673 | CMS |
| Incyte Corporation | $20,900.00 | 09/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169911 | CMS |
| Incyte Corporation | $12,500.00 | 09/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169675 | CMS |
| Incyte Corporation | $12,500.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141323201 | CMS |
| Incyte Corporation | $9,189.57 | 10/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169559 | CMS |
| Incyte Corporation | $2,012.50 | 10/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169677 | CMS |
| Incyte Corporation | $9,902.07 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169679 | CMS |
| Incyte Corporation | $287.50 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169681 | CMS |
| Incyte Corporation | $13,100.00 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169923 | CMS |
| Incyte Corporation | $7,722.68 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169635 | CMS |
| Incyte Corporation | $431.25 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141169913 | CMS |
| Stemline Therapeutics Inc. | $656.25 | 01/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964175 | CMS |
| Stemline Therapeutics Inc. | $131.25 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964178 | CMS |
| Stemline Therapeutics Inc. | $5,643.75 | 03/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964154 | CMS |
| Stemline Therapeutics Inc. | $105.65 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142964151 | CMS |
| Stemline Therapeutics Inc. | $6,300.00 | 04/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964157 | CMS |
| Stemline Therapeutics Inc. | $1,706.25 | 04/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964159 | CMS |
| Stemline Therapeutics Inc. | $3,543.75 | 04/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964161 | CMS |
| Stemline Therapeutics Inc. | $2,756.25 | 06/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964164 | CMS |
| Stemline Therapeutics Inc. | $1,050.00 | 09/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964167 | CMS |
| Stemline Therapeutics Inc. | $1,050.00 | 09/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1142964171 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.